Roth Capital Reiterates Buy On Regeneron Pharmaceuticals, $422 PT


In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target of $422.00.

Pantginis noted, “REGN announced that the NIH-sponsored study comparing effectiveness of Eylea to Avastin and Lucentis (Roche/Genentech, ROG.VX-NC) in diabetic macular edema (DME) patients achieved its primary endpoint. We believe this positive independent outcome will help further boost Eylea positioning as a superior treatment for DME compared to the competition.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -11.9% and a 33.1% success rate. Pantginis has a 32.1% average return when recommending REGN, and is ranked #3327 out of 3337 analysts.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts